Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (NEUTROSKIN)
Status
Conditions
Treatments
Details and patient eligibility
About
This study is to identify rare, disease-causing mutations of several rare neutrophil dermatoses. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated.
Full description
The origin of rare severe inflammatory skin diseases in dermatology is insufficiently known. They have in common the presence and activation of phagocytes, affect the quality of life through pain and inflammation and disfiguration, and can even be fatal. This study is intended to build on the findings that several of these neutrophil-mediated inflammatory dermatoses (NMID) have a genetic background and to identify rare, disease-causing mutations of several rare neutrophil dermatoses. This non-clinical case-control study is a research project with biological material and health-related data. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated. The data are obtained and verified using standardized methods as e.g. Nanostring, RNA sequencing and qRT-polymerase chain reaction (PCR), proteomics assays and immunohistochemistry as well as flow cytometry and imaging mass cytometry, ELISA, and Western Blot.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
- written consent of the participating person
- diagnosis of a disease in the NMID form group or proband of the control group
Exclusion Criteria for patients:
- Missing informed consent if samples collected after 2014
- no diagnosis of NMID
Exclusion Criteria for healthy controls:
- Missing informed consent
Trial design
3,370 participants in 4 patient groups
Trial contacts and locations
Loading...
Central trial contact
Emmanuel Contassot, Dr.; Alexander Navarini, Prof. Dr. med.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal